Liang Jian-Jing, Feng Wen-Jing, Li Ru, Xu Run-Tao, Liang Yu-Long
Department of Medicine, Hebei University, Baoding 071000, Hebei Province, China.
Department of General Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China.
World J Clin Cases. 2023 Feb 16;11(5):1058-1067. doi: 10.12998/wjcc.v11.i5.1058.
Thyroid cancer (TC) is a common malignant tumor in the endocrine system. In recent years, the incidence and recurrence rates of TC have been raising due to increasing work pressure and irregular lifestyles. Thyroid-stimulating hormone (TSH) is a specific parameter for thyroid function screening. This study aims to explore the clinical value of TSH in regulating the progression of TC, so as to find a breakthrough for the early diagnosis and treatment of TC.
To explore the value and safety of TSH in the clinical efficacy of patients with TC.
75 patients with TC admitted to the Department of Thyroid and Breast Surgery of our hospital from September 2019 to September 2021 were selected as the observation group, and 50 healthy subjects were selected as the control group during the same period. The control group was treated with conventional thyroid replacement therapy, and the observation group was treated with TSH suppression therapy. The soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35 levels, free triiodothyronine (FT), free tetraiodothyronine (FT), CD3, CD4, CD8, CD44V6, and tumor supplied group of factor (TSGF) levels were observed in the two groups. The occurrence of adverse reactions was compared between the two groups.
After treatment with different therapies, the levels of FT, FT, CD3, and CD4 in the observation group and the control group were higher than those before treatment, while the levels of CD8, CD44V6, and TSGF were lower than those before treatment, and the differences were statistically significant ( < 0.05). More importantly, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group after 4 wk of treatment, while the levels of IL-35 were higher than those in the control group, and the differences were statistically significant ( < 0.05). The levels of FT, FT, CD3 , and CD4 in the observation group were higher than those in the control group, and the levels of CD8, CD44V6, and TSGF were lower than those in the control group. There was no significant difference in the overall incidence rate of adverse reactions between the two groups ( > 0.05).
TSH suppression therapy can improve the immune function of patients with TC, lower the CD44V6 and TSGF levels, and improve serum FT and FT levels. It demonstrated excellent clinical efficacy and a good safety profile.
甲状腺癌（TC）是内分泌系统常见的恶性肿瘤。近年来，由于工作压力增加和生活方式不规律，TC的发病率和复发率一直在上升。促甲状腺激素（TSH）是甲状腺功能筛查的一个特定参数。本研究旨在探讨TSH在调节TC进展中的临床价值，以便为TC的早期诊断和治疗找到突破点。
探讨TSH在TC患者临床疗效中的价值和安全性。
选取2019年9月至2021年9月我院甲状腺乳腺外科收治的75例TC患者作为观察组，同期选取50例健康受试者作为对照组。对照组采用常规甲状腺替代治疗，观察组采用TSH抑制治疗。观察两组患者可溶性白细胞介素（IL）-2受体（sIL-2R）、IL-17、IL-35水平，游离三碘甲状腺原氨酸（FT）、游离甲状腺素（FT）、CD3、CD4、CD8、CD44V6及肿瘤相关生长因子（TSGF）水平。比较两组不良反应的发生情况。
采用不同治疗方法后，观察组和对照组的FT、FT、CD3及CD4水平均高于治疗前，而CD8、CD44V6及TSGF水平低于治疗前，差异有统计学意义（<0.05）。更重要的是，治疗4周后观察组的sIL-2R和IL-17水平低于对照组，而IL-35水平高于对照组，差异有统计学意义（<0.05）。观察组的FT、FT、CD3及CD4水平高于对照组，CD8、CD44V6及TSGF水平低于对照组。两组不良反应总发生率比较，差异无统计学意义（>0.05）。
TSH抑制治疗可提高TC患者的免疫功能，降低CD44V6和TSGF水平，提高血清FT和FT水平。其显示出优异的临床疗效和良好的安全性。
